Liraglutide is an injectable prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults and children who are 10 years of age and older with type 2 diabetes ...

Lupin has received approval from the Food and Drug Administration for liraglutide injection single-patient-use prefilled pens and glucagon for injection vials. Both of these products will be ...

Credit: Teva. The generic product is supplied in a prefilled, single-patient-use pen. The generic product is supplied in a prefilled, single-patient-use pen. Teva has launched an authorized generic ...

Hikma recently received the Food and Drug Administration’s permission for a new generic, and the company also launched two new generic products. The FDA approved Hikma's first generic referencing ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients with type 2 diabetes as a complement to diet and exercise. The FDA today ...

In a global move, Indian pharmaceutical company, Lupin on Friday has launched a generic diabetes medication in the US market. It has launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient ...

(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®. Liraglutide is ...

Approval of the once-daily injection, as an adjunct to diet and exercise, is intended to help with drug shortages and improve patient access. (HealthDay News) — The US Food and Drug Administration has ...